Pretreated blood inflammatory markers are potential predictive biomarkers in sarcoma
Pretreatment neutrophil lymphocyte ratio (NLR) and lymphocyte monocyte ratio (LMR) may be predictive of overall survival and disease-free survival in patients with bone sarcoma, according to a study.
After conducting a literature search, researchers identified 10 studies of 1845 cases of patients with bone sarcoma. Overall, 9 studies evaluated NLR, 7 evaluated platelet lymphocyte ratio (PLR), and 4 evaluated LMR.
According to pooled results, NLR that was higher prior to treatment was associated with worse overall survival and disease-free survival whereas a lower LMR was linked with worse overall survival. PLR was not found to be significantly predictive of the clinical outcomes of these patients.
Jiang M, Ma S, Hua Z, et al. Prognostic value of pretreated blood inflammatory markers in patients with bone sarcoma: A meta-analysis. Dis Markers. 2021;2021:8839512. DOI: 10.1155/2021/8839512. PMID: 33897913; PMCID: PMC8052170.